$AEMD News

Aethlon Medical Has Received A Notice Of Allowance For A U.S. Patent Titled "DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF".

Aethlon Medical Announces Preparedness For Ebola Outbreak, Reiterates Prepared For Investigational Use Of Its Hemopurifier Technology

AEMD: Hitting Key Milestones as Company Advances Clinical Study

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Announces Independent Data Safety Monitoring Board Completes Its Safety Review For AEMD-2022-06; Finds No Safety Concerns; Recommends Third And Final Cohort

OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCR

AEMD: Positive Takeaways From CEO Chat

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Said It Is Evaluating A Range Of Strategic Opportunities And Has Engaged Maxim As A Financial Advisor

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

AEMD: Advancing Oncology Trial; Seeking to Simplify - Potentially Broaden – Device Application

Aethlon Medical Inc (AEMD) Q3 2026 Earnings Call Highlights: Progress in Oncology Trials and ...

Aethlon Medical, Inc. Q3 2026 Earnings Call Summary

Aethlon Medical Inc (NASDAQ:AEMD) Reports Q3 2026 Results, Meeting Revenue Estimates and Beating on EPS

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Aethlon Medical Q3 EPS $(2.45) Beats $(2.57) Estimate

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026